HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Launches Propel Arden In Q1; Restaged Elizabeth Arden Rolling Out

This article was originally published in The Rose Sheet

Executive Summary

Elizabeth Arden Inc. attributes increased sales in the first quarter to strong fragrance launches. Meanwhile, earnings were impacted as the firm incurred expenses related to the restaging of its flagship Elizabeth Arden brand.

You may also be interested in...

Skin Devices, ‘Hair-ceuticals’ Are Opportunities For Firms That Avoid Pitfalls

Growth opportunities exist for firms marketing home-use skin-care devices and cosmeceuticals in new categories such as hair care, but such products also can invite regulatory scrutiny for exceeding FDA’s definition of a cosmetic. Consulting with FDA on a premarket basis and crafting claims with attention to regulatory parameters can help firms stay in the agency’s good graces.

Arden “Rings In The Holidays” With Counter Sampling, Promos

Elizabeth Arden prepares for the holiday season with increased staffing, sampling and a unique promo for celebrity fragrances in certain stores, the beauty firm reports during first quarter earnings call Oct. 30. With renovation of its doors and counters largely completed, firm focuses on driving counter productivity in highest-potential doors.

Arden Books Gains, But Projections Were “Too Optimistic”

Elizabeth Arden Inc reports a second-quarter sales increase of nearly 9%, but the firm missed its projections for the holidays. Recent launches from Justin Beiber, Nicki Minaj and Taylor Swift franchises drove sales in the US prestige category.

Related Content

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts